NRSN (NeuroSense Therapeutics) Marketable Securities: $0.00 Mil (As of Dec. 2025)


NRSN NeuroSense Therapeutics Ltd NRSN
31 GF Score
Price $0.70
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Marketable Securities?

NeuroSense Therapeutics NRSN -1.82% 31 Marketable Securities is $0.00 Mil as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. NeuroSense Therapeutics's Marketable Securities for the quarter that ended in Dec. 2025 was $0.00 Mil.

NeuroSense Therapeutics  (NAS:NRSN) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

NeuroSense Therapeutics Marketable Securities Related Terms

NeuroSense Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Marketable Securities Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 3.55 0.00 0.00 0.00

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NRSN
31GF Score
NeuroSense Therapeutics Ltd NRSN
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
NeuroSense Therapeutics (NRSN) has a Marketable Securities of $0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' Marketable Securities too high?
NeuroSense Therapeutics' current Marketable Securities is $0.00 Mil. Overall, NeuroSense Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Marketable Securities compare to SER and PVCT?
NeuroSense Therapeutics' Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. NeuroSense Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Marketable Securities is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
31GF Score

Get the complete analysis for NRSN

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price